Study S002150

Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04998136
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 150
Start: 2022-08-15
Primary completion: 2023-10-16
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide 2.4 mg; DRUG:Placebo (semaglutide 2.4 mg)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1265-5285

Registered primary outcomes

Change in Body Weight (%) : In-trial Observation Period [Baseline (week 0), end of treatment (week 44)]
Change in Body Weight (%) : On-treatment Observation Period [Baseline (week 0), end of treatment (week 44)]
Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : In-trial Observation Period [At week 44]
Number of Participants Achieved More Than or Equal to (≥) 5 Percent (%) Body Weight Reduction (Yes/no) : On-treatment Observation Period [At week 44]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016602	Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. Lim S, The lancet. Diabetes & endocrinology	2025	Randomized trial	PMID 40825340 DOI	cites ClinicalTrials.gov:NCT04998136; registry reference DERIVED:40825340